This morning I had the privilege of presenting virtually at the Global Longevity Federation 2026 conference in Rome, Italy, one of the leading international gatherings in aging science and longevity medicine. My talk: Plasmapheresis (Therapeutic Plasma Exchange) for Healthspan Extension.
The room was filled with researchers, clinicians, and biotech leaders from across Europe and beyond, all focused on the same question: how do we extend not just lifespan, but the years spent in genuine health?
What I Covered
Therapeutic plasma exchange (TPE), also called plasmapheresis, removes aging factors from the blood plasma and replaces them with clean albumin. It is FDA-cleared, outpatient, and backed by published human data showing 1–3 years of biological age reduction, 52–71% slowing of Alzheimer's progression (AMBAR study), and meaningful improvements in long COVID patients.
I also addressed the safety profile directly. Compared to FDA-approved Alzheimer's drugs carrying a 12–40% risk of brain swelling, TPE carries no meaningful risk of brain swelling, making it 20–70 times safer with comparable or superior outcomes.
For anyone at the conference or following the GLF 2026 program who wants to go deeper on the science, our website covers the full evidence base, including the published research, candidacy criteria, and what to expect from treatment.
TPE for Longevity: Growing Interest in Europe and California
Interest in therapeutic plasma exchange for healthy aging is growing rapidly, both in Europe and in California, where Global Apheresis has been providing TPE for longevity, Alzheimer's, and long COVID since our founding. Conferences like GLF 2026 are an important part of moving this conversation from the research lab into mainstream clinical practice.
If you are a clinician, researcher, or patient exploring plasmapheresis for healthspan extension in California or internationally, we welcome the conversation.